Psyence BioMed agrees to invest up to $5 million in ibogaine firm PsyLabs
Psyence Labs Issuer · Psyence BioMed Investor
Intelligence
The deal
- Type
- Funding
- Amount
- up to $5M
- Structure
- up to US$5M cash investment, of which US$2.4M committed, plus a ~US$9M value-matched share exchange
- Status
- Announced
- Round
- strategic investment
- Valuation
- Not recorded
- Region
- United States
- Date
- 23 September 2026
As of this development: a later development may record new terms.
Lifecycle
- Announced
- Closed
The parties
Psyence Labs Issuer
Psyence BioMed Investor
Activity